Antidepressant-like effects of buprenorphine in rats are strain dependent

Behavioural Brain Research

Volumn 278, Issue , 2015, Pages 385-392

  Browne, Caroline A ^a   van Nest, Duncan S ^a   Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Buprenorphine; Emergence test; FST; Treatment resistant depression; Wistar Kyoto rat

Indexed keywords

BUPRENORPHINE; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG SENSITIVITY; EMERGENCE TEST; EXPERIMENTAL BEHAVIORAL TEST; FORCED SWIM TEST; IMMOBILITY; MAJOR DEPRESSION; MALE; NONHUMAN; PHENOTYPE; RAT; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; TRANQUILIZING ACTIVITY; WISTAR KYOTO RAT; ANIMAL; BODY WEIGHT; CATALEPSY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY; SPECIES DIFFERENCE; SWIMMING; TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BODY WEIGHT; BUPRENORPHINE; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FREEZING REACTION, CATALEPTIC; MALE; MOTOR ACTIVITY; RATS; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SWIMMING; TIME FACTORS;

EID: 84910024220     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.10.014     Document Type: Article

References (61)

1. Kessler R.C., et al. Prevalence: severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):617-627.
2. Trivedi M.H., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354(12):1243-1252.
3. Fava M., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR×D report. Am J Psychiatry 2008, 165(3):342-351.
4. Trivedi M.H., et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008, 69(2):246-258.
5. Olchanski N., et al. The economic burden of treatment-resistant depression. Clin Ther 2013, 35(4):512-522.
6. Armario A., Gavalda A., Marti J. Comparison of the behavioural and endocrine response to forced swimming stress in five inbred strains of rats. Psychoneuroendocrinology 1995, 20(8):879-890.
7. Pare W.P. "Behavioral despair" test predicts stress ulcer in WKY rats. Physiol Behav 1989, 46(3):483-487.
8. Lopez-Rubalcava C., Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 2000, 22(2):191-199.
9. Nam H., et al. Learned helplessness and social avoidance in the Wistar-Kyoto rat. Front Behav Neurosci 2014, 8:109.
10. Pare W.P. The performance of WKY rats on three tests of emotional behavior. Physiol Behav 1992, 51(5):1051-1056.
11. Pare W.P. Learning behavior: escape behavior, and depression in an ulcer susceptible rat strain. Integr Physiol Behav Sci 1992, 27(2):130-141.
12. Pare W.P. Hyponeophagia in Wistar Kyoto (WKY) rats. Physiol Behav 1994, 55(5):975-978.
13. Pare W.P. Open field: learned helplessness, conditioned defensive burying, and forced-swim tests in WKY rats. Physiol Behav 1994, 55(3):433-439.
14. Carr G.V., Lucki I. Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology (Berl) 2010, 210(2):295-302.
15. Rittenhouse P.A., et al. Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology 2002, 27(3):303-318.
16. Pardon M.C., Ma S., Morilak D.A. Chronic cold stress sensitizes brain noradrenergic reactivity and noradrenergic facilitation of the HPA stress response in Wistar Kyoto rats. Brain Res 2003, 971(1):55-65.
17. Pare W.P., et al. Gender differences in acute and chronic stress in Wistar Kyoto (WKY) rats. Integr Physiol Behav Sci 1999, 34(4):227-241.
18. Dugovic C., et al. Sleep in the Wistar-Kyoto rat: a putative genetic animal model for depression. NeuroReport 2000, 11(3):627-631.
19. Tejani-Butt S., Kluczynski J., Pare W.P. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(1):7-14.
20. Will C.C., Aird F., Redei E.E. Selectively bred Wistar-Kyoto rats: an animal model of depression and hyper-responsiveness to antidepressants. Mol Psychiatry 2003, 8(11):925-932.
21. Lahmame A., Armario A. Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants?. Psychopharmacology (Berl) 1996, 123(2):191-198.
22. Rosenfeld A., Weller A. Behavioral effects of environmental enrichment during gestation in WKY and Wistar rats. Behav Brain Res 2012, 233(2):245-255.
23. Solberg L.C., et al. Altered hormone levels and circadian rhythm of activity in the WKY rat: a putative animal model of depression. Am J Physiol Regul Integr Comp Physiol 2001, 281(3):R786-R794.
24. Bruchas M.R., et al. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One 2009, 4(12):e8528.
25. Knoll A.T., Carlezon W.A. Dynorphin, stress, and depression. Brain Res 2010, 1314:56-73.
26. Land B.B., et al. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008, 28(2):407-414.
27. Mague S.D., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003, 305(1):323-330.
28. McLaughlin J.P., Marton-Popovici M., Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003, 23(13):5674-5683.
29. McLaughlin J.P., et al. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006, 31(4):787-794.
30. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008, 33(3):643-652.
31. Pearson K.A., et al. Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats. Neuropsychopharmacology 2006, 31(11):2449-2461.
32. Carr G.V., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 2010, 35(3):752-763.
33. Bechtholt A.J., Hill T.E., Lucki I. Anxiolytic effect of serotonin depletion in the novelty-induced hypophagia test. Psychopharmacology (Berl) 2007, 190(4):531-540.
34. Bodnoff S.R., et al. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 1988, 95(3):298-302.
35. Lutfy K., Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004, 2(4):395-402.
36. Emrich H.M., Vogt P., Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann NY Acad Sci 1982, 398:108-112.
37. Bodkin J.A., et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995, 15(1):49-57.
38. Nyhuis P.W., Gastpar M., Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 2008, 28(5):593-595.
39. Karp J.F.B., Butters M.A., Begley A., Miller M.D., Lenze E.J., Blumberger D., et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in mid-life and older adults. J Clin Psychiatry 2014, 75:e785-e793.
40. Falcon E.M., Maier K., Robinson S.A., Hill-Smith T.E., Lucki I. Buprenorphine produces antidepressant-like and anxiolytic behavioral responses in mice. Psychopharmacology (Berl) 2014, 10.1007/s00213-014-3723-y.
41. Pare W.P., Tejani-Butt S., Kluczynski J. The emergence test: effects of psychotropic drugs on neophobic disposition in Wistar Kyoto (WKY) and Sprague Dawley rats. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25(8):1615-1628.
42. Lieben C.K., et al. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav Brain Res 2004, 151(1-2):53-64.
43. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121(1):66-72.
44. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005, 29(4-5):547-569.
45. Henry R., Casto R., Printz M.P. Diurnal cardiovascular patterns in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1990, 16(4):422-428.
46. Pare W.P., Kluczynski J. Differences in the stress response of Wistar-Kyoto (WKY) rats from different vendors. Physiol Behav 1997, 62(3):643-648.
47. Kurtz T.W., et al. Molecular evidence of genetic heterogeneity in Wistar-Kyoto rats: implications for research with the spontaneously hypertensive rat. Hypertension 1989, 13(2):188-192.
48. Sittig L.J., et al. Phenotypic instability between the near isogenic substrains BALB/cJ and BALB/cByJ. Mamm Genome 2014, 10.1007/s00335-014-9531-1.
49. Sagvolden T., et al. Behavioral and genetic evidence for a novel animal model of attention-deficit/hyperactivity disorder predominantly inattentive subtype. Behav Brain Funct 2008, 4:56.
50. Zhang-James Y., Middleton F.A., Faraone S.V. Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources. Physiol Genomics 2013, 45(13):528-538.
51. Durand M., et al. Strain-dependent neurochemical and neuroendocrine effects of desipramine: but not fluoxetine or imipramine, in spontaneously hypertensive and Wistar-Kyoto rats. Neuropharmacology 2000, 39(12):2464-2477.
52. Zhang H., et al. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 2007, 570(1-3):89-96.
53. Beardsley P.M., et al. Differential effects of the novel kappa opioid receptor antagonist: JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 2005, 183(1):118-126.
54. Pietrzak R.H., et al. Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry 2014, 10.1001/jamapsychiatry.2014.1221.
55. Hurd Y.L. Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol Psychiatry 2002, 7(1):75-81.
56. Anderson S.A., et al. Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression. J Clin Invest 2013, 123(12):5334-5341.
57. Yuferov V., et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14(12):793-804.
58. Bruchas M.R., Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) 2010, 210(2):137-147.
59. Bruchas M.R., et al. Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011, 71(3):498-511.
60. Lemos J.C., et al. Repeated stress dysregulates kappa-opioid receptor signaling in the dorsal raphe through a p38alpha MAPK-dependent mechanism. J Neurosci 2012, 32(36):12325-12336.
61. Tizabi Y., et al. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 2012, 213:72-80.